[The first answer to viral infections: type I interferon].
The interferon system is part of the innate immune system in vertebrates. It represents the first line of host defence against viral infections. Virus entry triggers intracellular signalling pathways which lead to the secretion of soluble factors such as interferons and other cytokines. Interferons signal to neighbouring cells that a viral infection has occurred and induce an "antiviral state" resulting in inhibition of virus replication. The first recombinant interferons were produced in the 1980ies and were considered to be a major breakthrough. At present, interferons are routinely used in the therapy of certain viral and autoimmune diseases as well as for neoplastic disorders in man. In 2001 the first interferon preparation for veterinary use was licensed in the European Union. This review summarises the molecular mechanisms of the interferon system and the viral counteractions. The current type I interferon therapies in humans are described and an overview of recent clinical studies in veterinary medicine, including cat, dog, horse, cow, sheep, pig, and poultry, is given. We review the potential application of interferons and arguments in favor or against its therapeutic use in veterinary medicine.
Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Freiburg, Deutschland. andreas.pichlmair@cancer.org.uk
Andreas
A
Pichlmair
Matthias
M
Pollak
Andreas
A
Bergthaler
D000818:Animals; D000829:Animals, Domestic; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007113:Immunity, Innate; D007370:Interferon Type I / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use*; D014730:Veterinary Medicine / Q000379:methods; D014777:Virus Diseases / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D014780:Viruses / Q000276:immunology*
D000998:Antiviral Agents; D007370:Interferon Type I